In this interview, Dennis Bruemmer MD, PhD and Alison L. Bailey MD FACC, discuss Optimizing the Care of ASCVD Patients with T2DM.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

In this interview, David J. Maron MD, FACC and Richard A. Chazal MD, MACC, discuss Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

What are the practical considerations when determining the duration of antiplatelet regimens following PCI?  In this interview, Mirvat Alasnag, FACP, FACC, FSCAI, FSCCT, and Sun Moon Kim, MD, FSCAI, FACC, discuss Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

In this interview, Harriette GC Van Spall MD, MPH, FRCPC, and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.), discuss the Basics of HF-rEF and Work Up.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy.    In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EX ..read more

Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side effects.  In this interview, Steven E. Nissen MD, MACC and Laxmi Mehta MD, FACC, discuss Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

  Obesity is a driver of Type 2 diabetes, hypertension, abnormal lipids and is an independent risk factor for cardiovascular events and death.  The recent discovery of medications with robust ability to affect appetite is making successful and maintained weight loss a reality. In individuals with obesity, semaglutide produces 17% weight loss on average and tirzepatide, under review by the FDA, 22% weight loss on average. While cost and expertise in prescribing are still barriers to implementation in practice, these new medications offer promise in fighting the ever rising rates of ob ..read more

In this interview, Michael J. Ackerman MD, PhD, and Christopher M. Kramer MD, FACC, with Jeffrey Hsu MD, PhD, discuss ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  ..read more

  Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a multicenter, randomized, double-blind, placebo-controlled study presented at ACC.23/WCC.  In this interview, Bonnie Ky MD, MSCE and Anthony N. DeMaria MD, MACC discuss “Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial.”  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL   ..read more

Clinicians need more tools to reduce the number of unnecessary tests. Clinical likelihood models represent such tools, and this study demonstrated favorable prognosis for patients who were deferred for testing using the risk factor-weighted clinical likelihood model and the coronary artery calcium score-weighted clinical likelihood model.  In this interview, Simon Winther MD, PhD and Laxmi Mehta MD, FACC discuss JACC piece: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL ..read more